The 7th Joint ECTRIMS-ACTRIMS Meeting, taking place in Paris this month, is one of the largest scientific conferences focused solely on multiple sclerosis (MS), and the National Multiple Sclerosis Society will be among the many interested parties attending.
To get a feeling for meeting highlights and presentations the society will follow most closely, Multiple Sclerosis News Today spoke to Bruce Bebo, executive vice president for research at the National MS Society.
Fresh information on outcomes in recent scientific studies, Bebo said, “is an incredibly important activity to advance progress in MS research and MS care.”
The joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) runs Oct. 25–28.
Progressive MS research in the spotlight
While information on more than 5,000 ECTRIMS presentations was only released this week, Bebo appeared to have his focus set — progressive MS.
“I think the presentation I’m most excited about is the reporting of results from the SPRINT-MS trial,” he said. The Phase 2 study (NCT01982942) — partly sponsored by the National MS Society — explored MediciNova’s ibudilast in people with both primary and secondary progressive MS.
With the trial recently completed, researchers will present data on how the drug managed to impact brain tissue loss and other disease parameters.
Also on Bebo’s list is a presentation by lead investigators of the Global Collaborative Network of the International Progressive MS Alliance.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?